Clinical trial
Safety and Exercise Study of Two Doses of BMN 110 for Morquio A Syndrome
Abstract
The primary objective of this study was to evaluate the safety of a 2.0 mg/kg/week and a 4.0 mg/kg/week of BMN 110 in patients with Morquio A syndrome for up to 196 weeks. Secondary objectives were to investigate the effect of the two doses on exercise capacity for up to 196 weeks. In addition, the pharmacokinetic (PK) parameters of both doses of BMN 110 was assessed.
Topics & conditions
Detected automatically by Psychedelic Commons from the title and abstract, not labels from the source. They may be incomplete.
Keywords
Psychedelic Commons aggregates metadata from open sources and links back to the original. Rights remain with the authors and publishers. Something wrong with this record? Report a problem.
Related research
ArticlePsilocybin
MFCC-DFT mapping of ligand recognition at the 5-HT<sub>2A</sub> receptor: energetic analysis of the interactions between serotonin, psychedelics, and antipsychotics.
ArticleLSD
LSD modulates effective connectivity and neural adaptation mechanisms in an auditory oddball paradigm.
ArticleLSD